All posts tagged
More News! Allergan sees Patient Deaths, New Alzheimer’s Targets?
Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease
The Patent Office has Spoken: What does it Mean for CRISPR in Europe?
UPDATE: No Clear Winner in the CRISPR Patent Battle
How much of a Gamble is Investing in CRISPR?
CRISPR Therapeutics applies to go Public in another Massive IPO
“CRISPR is highly fragmented, with too many approaches. We bring it all together”
The 5 things outside Europe you need to know this week (Alphabet, Editas, Retrophin)
German Viral Vector Producer SIRION pursues its American dream and opens in Boston
Review: The CRISPR’s Therapeutical revolution
Labiotech UG, All Rights Reserved -
Send this to friend